Bifogade filer
Lifecare implants first consistently manufactured implant
Prenumeration
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Bergen, Norway, 16 December 2025 - Lifecare ASA (LIFE), a MedTech company developing next-generation implantable Continuous Glucose Monitoring (CGM) technology, today announces that the first implant from a new production batch has been successfully implanted, marking an important step in demonstrating manufacturing reproducibility and process control under the company’s updated production protocol.
The manufacturing milestone relates to the full implantable product, integrating Lifecare’s proprietary sensing technology with electronics, wireless communication and encapsulation into a medical-grade device designed for implantation. While Lifecare has previously demonstrated the ability to produce individual sensor components, the ability to reproducibly manufacture the complete implant as a functional and implantable product represents a significant step forward in the company’s development.
The implant, delivered by Lifecare’s development partner TTP plc, successfully completed laboratory testing, functional handover testing, sterilisation and sterility confirmation prior to implantation on 9 December 2025 at the Faculty of Veterinary Medicine, Department of Companion Animal Clinical Sciences at the Norwegian University of Life Sciences (NMBU).
Following implantation, electrical functionality and communication with the external read-out device (collar) have been confirmed. The implant is now being monitored in accordance with Lifecare’s established study protocol.
“This milestone is important for several reasons,” says Joacim Holter, CEO of Lifecare. “Our sensing technology has previously demonstrated reliable glucose responsiveness in humans, and this has again been confirmed through laboratory testing. What is particularly significant at this stage is that these results are now achieved using an improved implant manufactured as a complete product under our updated production protocol. This marks a clear transition from validating the underlying technology to demonstrating our ability to reproducibly manufacture high-quality, implantable devices in a controlled and repeatable manner, incorporating the improvements we have made across design, materials and production.”
The implantation represents the first use of Lifecare’s most advanced implant generation to date in a live tissue setting, manufactured under the updated protocol. Additional fully functional implants from the same production batch have been manufactured and tested under Lifecare’s updated production protocol and are planned for use in further implantations as part of Lifecare’s ongoing trial.
This development represents a key step in Lifecare’s transition from technology development to execution, supporting continued progress toward veterinary market entry and future clinical programs.